日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

GCGR (Volagidemab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號:
    CSB-RA009316MB2HU
  • 規(guī)格:
    ¥83486
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品描述:
    GCGR (Volagidemab Biosimilar Antibody) 重組單克隆抗體是一種靶向胰高血糖素受體(別名包括Glucagon receptor、GL-R、GCGR)。該抗體以重組人GCGR蛋白制備,具有高度的人源種屬反應(yīng)性,能夠特異性識別并結(jié)合人胰高血糖素受體,從而發(fā)揮生物學(xué)效應(yīng)。 Volagidemab Biosimilar Antibody因其對胰高血糖素受體的特異性抑制作用,成為2型糖尿病治療的潛在新選擇。胰高血糖素受體在血糖調(diào)節(jié)中起關(guān)鍵作用,通過阻斷該受體可減少肝糖原分解和葡萄糖生成,進(jìn)而降低血糖水平。相關(guān)研究表明,該抗體研發(fā)的藥物可能與胰島素或其他降糖藥物聯(lián)合使用,改善血糖控制效果,尤其適用于胰島素抵抗或β細(xì)胞功能受損的患者。目前,針對其安全性和有效性的臨床試驗(yàn)正在進(jìn)行中,探索不同劑量方案下的血糖調(diào)控效果及長期用藥的耐受性。 GCGR重組單克隆抗體為代謝疾病機(jī)制研究提供了重要工具。研究人員可利用其特異性結(jié)合特性,在細(xì)胞模型和動物模型中深入探究胰高血糖素受體的信號通路、生理功能及與其他代謝通路的相互作用。此外,該抗體也可用于開發(fā)基于GCGR靶點(diǎn),或作為陽性對照用于新的GCGR拮抗劑篩選,為糖尿病及相關(guān)代謝綜合征的新藥研發(fā)奠定基礎(chǔ)。其高度的種屬反應(yīng)性確保了在人源化實(shí)驗(yàn)體系中的可靠性,推動了從基礎(chǔ)研究到臨床轉(zhuǎn)化的進(jìn)程。
  • Uniprot No.:
  • 基因名:
  • 別名:
    Glucagon receptor;GL-R, GCGR
  • 反應(yīng)種屬:
    Human
  • 免疫原:
    Recombinant Human GCGR protein
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標(biāo)記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    0.01M PBS,pH7.4
  • 產(chǎn)品提供形式:
    Liquid
  • 應(yīng)用說明:
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    In stock
  • 用途:
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

  • 功能:
    G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.
  • 基因功能參考文獻(xiàn):
    1. 3.0 A-resolution crystal structure of the full-length human glucagon receptor (GCGR) in complex with a glucagon analogue and partial agonist, NNC1702 PMID: 29300013
    2. work toward the mapping of interactions between the polypeptide hormone glucagon and the glucagon receptor PMID: 28508109
    3. 3.0 A crystal structure of full-length GCGR containing both the extracellular domain and transmembrane domain in an inactive conformation PMID: 28514451
    4. This work suggests that RAMP2 may modify the agonist activity and trafficking of the GCGR, with potential relevance to production of new peptide analogs with selective agonist activities. PMID: 28586439
    5. Data suggest that GCGR activation proceeds via a mechanism in which transmembrane helix 6 (TM6) is held in an inactive conformation by a conserved polar core and a hydrophobic lock (involving intracellular loop 3, IC3); mutations in the corresponding polar core of GCGR disrupt these inhibitory elements, allow TM6 to swing outward, and induce constitutive G protein signaling. PMID: 28356352
    6. The activation of the GCGR is characterized by the outward movement of the intracellular side of helix VI. In the active state of the GCGR, the Arg173(2.46)-Ser350(6.41) and Glu245(3.50)-Thr351(6.42) hydrogen bonds break, and the chi1 rotamer of Phe322(5.54) changes from perpendicular to parallel to helix VI. PMID: 27094704
    7. In the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), the extracellular domain is required for signaling even when the hormone is covalently linked to the transmembrane domain. PMID: 27226600
    8. 2.5 A crystal structure of human GCGR in complex with the antagonist MK-0893, which is found to bind to an allosteric site outside the seven transmembrane helical bundle in a position between TM6 and TM7 extending into the lipid bilayer PMID: 27111510
    9. Molecular dynamics and disulfide crosslinking studies suggest that apo-GCGR can adopt both an open and closed conformation associated with extensive contacts between the ECD and 7TM domain. Glucagon binds to GCGR by a conformational selection mechanism. PMID: 26227798
    10. glucagon cell adenomatosis with GCGR germline mutations seems to follow an autosomal-recessive trait. PMID: 25695890
    11. Using a real-time time-resolved FRET-based internalization assay, we show that GLP-1R, GIPR, and GCGR internalize with differential properties PMID: 25451942
    12. crystal structure of the seven transmembrane helical domain of human GCGR at 3.4 A resolution, and a hybrid model of glucagon bound to GCGR to understand the molecular recognition of the receptor for its native ligand PMID: 23863937
    13. Letter/Case Report: nonfunctional glucagon cell adenomatosis with no detectable glucagon receptor mutations. PMID: 23407487
    14. GRA1 is a potent glucagon receptor antagonist with strong antihyperglycemic efficacy in preclinical models and prominent effects on hepatic gene-expression related to amino acid metabolism PMID: 23185367
    15. F22, V23, M27, and D15 of GCGR are the most important residues for glucagon binding. PMID: 22893257
    16. in addition to activation of the classic cAMP/protein kinase A (PKA) pathway, activation of GCGR also induced beta-catenin stabilization and activated beta-catenin-mediated transcription PMID: 22438981
    17. analysis of glucagon receptor antagonists with reduced molecular weight and lipophilicity PMID: 22119466
    18. The P86S mutant GCGR shows abnormal receptor internalization & calcium mobilization, & causes apoptosis. It cases Mahvash disease (hyperglucagonemia, hypoglycemia, pancreatic neuroendocrine tumors). PMID: 21680267
    19. substituted cysteine accessibility method and 3D-molecular modeling to study the N-terminal domain; results showed that Asp(63), Arg(116), and Lys(98) are essential for the receptor structure and/or ligand binding PMID: 20647307
    20. The [Ca2+] response is induced by glucagon mainly via the coupling of GCGR to the Galphaq/11 and Galphai/o proteins. PMID: 19903011
    21. The Gly40Ser polymorphism of the GCGR gene is associated with higher risk of hypertension and with enhanced proximal tubular sodium reabsorption. PMID: 11692154
    22. Gly40Ser mutation in the glucagon receptor gene is not associated with type 2 diabetes in a Brazilian population, but a reduction of insulin secretion was observed in Gly40Ser carriers. PMID: 11961492
    23. Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus PMID: 12724331
    24. Expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha), known to be upregulated in the liver by fasting, was found to abolish the cAMP-dependent downregulation of glucagon receptor mRNA expression in vitro. PMID: 17374560

    顯示更多

    收起更多

  • 亞細(xì)胞定位:
    Cell membrane; Multi-pass membrane protein.
  • 蛋白家族:
    G-protein coupled receptor 2 family
  • 數(shù)據(jù)庫鏈接:

    HGNC: 4192

    OMIM: 138033

    KEGG: hsa:2642

    STRING: 9606.ENSP00000383558

    UniGene: Hs.208



×